Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
KNSA
KNSA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KNSA News
Kiniksa to Speak at TD Cowen Health Conference
Feb 25 2026
Yahoo Finance
Kiniksa Pharmaceuticals Q4 2025 Earnings Highlights
Feb 24 2026
seekingalpha
Kiniksa Pharmaceuticals Q4 2025 Earnings Report
Feb 24 2026
seekingalpha
Kiniksa Reports Strong 2025 Financials with 62% Growth in ARCALYST Sales
Feb 24 2026
Newsfilter
Kiniksa Pharmaceuticals Set to Announce Q4 Earnings
Feb 23 2026
seekingalpha
Kiniksa Reports $677.5M in 2025 ARCALYST Revenue, 62% Growth
Jan 12 2026
Globenewswire
Kinaset Therapeutics Closes $103 Million Series B Financing to Advance Inhaled Asthma Treatment
Jan 11 2026
Businesswire
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
Nov 19 2025
NASDAQ.COM
Kiniksa Pharmaceuticals Executive Offloads Shares Valued at $1,962,781, Recent SEC Filing Reveals
Oct 22 2025
Yahoo Finance
Analysis Indicates VBK Could Reach $342
Oct 22 2025
NASDAQ.COM
Wells Fargo Keeps Overweight Rating on Kiniksa Pharmaceuticals and Increases Price Target to $45
Sep 25 2025
Benzinga
Zacks Industry Outlook Spotlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals, and Twist BioScience
Sep 24 2025
NASDAQ.COM
Kiniksa Pharmaceuticals International, plc (KNSA) Shows Promising Momentum: Reasons for Potential Sustainability
Sep 19 2025
NASDAQ.COM
7 Biotech Stocks Reaching 52-Week Highs - Will the Uptrend Persist?
Sep 15 2025
NASDAQ.COM
Cytokinetics Rises Following Encouraging Late-Stage Study Results for Cardiomyopathy
Sep 03 2025
NASDAQ.COM
Understanding the Recent Price Movement of Kiniksa Pharmaceuticals International, plc (KNSA) and Its Benefits
Sep 03 2025
NASDAQ.COM
Show More News
